BiotechTube
First Ascent Medical

First Ascent Medical

Denver, United States· Est.
firstascentbiomedical.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3M

Overview

First Ascent Biomedical is a private, pre-revenue biotech startup pioneering a functional precision medicine platform for oncology. Its xDRIVE system tests up to 150+ FDA-approved drugs and combinations directly on a patient's live cancer cells (from solid or liquid tumors), integrating this functional data with genomics and AI to generate personalized treatment recommendations. The company targets three customer segments: patients/oncologists seeking alternative options, pharmaceutical companies for drug development, and research institutions. Validated through collaborations with top cancer centers, its platform promises to shift cancer care from standardized protocols to individualized treatment plans.

Oncology

Technology Platform

xDRIVE (Ex Vivo Drug Response Identification & Validation Engine): A platform combining ex vivo functional drug sensitivity testing on live patient tumor cells, genomic sequencing, and AI-powered cancer weakness mapping to identify personalized treatment options.

Funding History

1
Total raised:$3M
Seed$3M

Opportunities

The company addresses a major unmet need in late-line cancer care, where patients have few options.
Its rapid 10-day service and dual focus on clinical care and drug development create two significant revenue streams.
Growing acceptance of precision medicine and AI in oncology presents a favorable market trend.

Risk Factors

Key risks include the need for extensive clinical validation to drive adoption and reimbursement, technical challenges in reliably culturing diverse tumor types, and competition from other functional testing platforms.
As a private, pre-revenue startup, it also faces significant financial execution risk.

Competitive Landscape

First Ascent competes in the functional precision oncology space against companies using patient-derived organoids or other ex vivo assay technologies. It differentiates on speed (10-day turnaround) and the integration of functional data with AI. It is complementary to, but also competitive with, NGS-based genomic profiling companies by adding a direct functional response layer.

More companies in Diagnostics & Precision Medicine →More companies in United States →